3-[3-amino-5-(1-ethyl-1H-indazol-5-yl)-4-(indan-2-yloxy)phenyl]propionic acid | 590415-96-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 3-[3-amino-5-(1-ethyl-1H-indazol-5-yl)-4-(indan-2-yloxy)phenyl]propionic acid
• 英文别名: 3-[3-amino-4-(2,3-dihydro-1H-inden-2-yloxy)-5-(1-ethylindazol-5-yl)phenyl]propanoic acid
• CAS: 590415-96-6
• 化学式: C₂₇H₂₇N₃O₃
• 分子量: 441.53
• InChiKey: JLUIPERNESBRPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  90.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Substituted phenylalkanoic acid derivatives and use thereof
  申请人：——

  公开号：US20040044258A1

  公开（公告）日：2004-03-04

  A compound represented by the formula (I) or a salt thereof: 1 wherein n represents an integer of 1 to 3, R represents an alkyl group having 3 to 8 carbon atoms, a group represented by the following formula: R 1 (CH 2 ) k — (wherein k represents 0 or an integer of 1 to 3; R 1 represents a saturated cyclic alkyl group having 3 to 7 carbon atoms or a saturated condensed cyclic alkyl group having 6 to 8 carbon atoms, and the group R 1 may be substituted with a lower alkyl group having 1 to 4 carbon atoms) and the like, and Ar represents a condensed bicyclic group such as naphthalen-1-yl group, which has suppressing action on prostaglandin and leukotriene production and is useful for prophylactic and/or therapeutic treatment of various inflammatory diseases and the like caused by these lipid mediators.

  化合物的化学式为（I）或其盐： 其中n表示1到3的整数，R表示具有3到8个碳原子的烷基基团，由以下化学式表示的基团：R1(CH2)k—（其中k表示0或1到3的整数；R1表示具有3到7个碳原子的饱和环烷基基团或具有6到8个碳原子的饱和紧凑环烷基基团，基团R1可以被具有1到4个碳原子的较低烷基基团取代）等，Ar表示如萘-1-基团等的紧凑双环基团，具有对前列腺素和白三烯生成的抑制作用，对由这些脂质介质引起的各种炎症性疾病等的预防和/或治疗治疗有用。
• Novel crystal forms of substituted phenylalkanoic acids and process for producing the same
  申请人：Arimoto Yuichi

  公开号：US20080070967A1

  公开（公告）日：2008-03-20

  [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. [Means] Crystals of any compound among 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, and methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate, and methods of producing the same are provided.

  【对象】在使用3- [3-氨基-4-（茚-2-氧基）-5-（1-甲基-1H-吲唑-5-基）苯基]丙酸，甲基3- [4-（茚-2-氧基）-3-（1-甲基-1H-吲唑-5-基）-5-硝基苯基]丙酸酯或甲基3- [3-氨基-4-（茚-2-氧基）-5-（1-甲基-1H-吲唑-5-基）苯基]丙酸酯作为药物时，提供了更可取的方面或改进的方法。 【手段】提供了3- [3-氨基-4-（茚-2-氧基）-5-（1-甲基-1H-吲唑-5-基）苯基]丙酸，甲基3- [4-（茚-2-氧基）-3-（1-甲基-1H-吲唑-5-基）-5-硝基苯基]丙酸酯和甲基3- [3-氨基-4-（茚-2-氧基）-5-（1-甲基-1H-吲唑-5-基）苯基]丙酸酯中的任何一种化合物的晶体以及制备它们的方法。
• STABLE PHARMACEUTICAL COMPOSITION
  申请人：SUZUKI Kazumi

  公开号：US20100041725A1

  公开（公告）日：2010-02-18

  A pharmaceutical composition comprising a compound represented by the general formula (I): or a salt thereof, and a pharmaceutically acceptable carrier, wherein the composition does not substantially contain a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, or when the composition contains a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, contact of the reducing sugar and the compound represented by the general formula (I) or a salt thereof is eliminated.

  一种药物组合物，包括下列通式（I）所表示的化合物或其盐，以及一种药学上可接受的载体。其中，该组合物不含有可还原糖和/或含有可还原糖的载体作为药学上可接受的载体成分，或者当该组合物含有可还原糖和/或含有可还原糖的载体作为药学上可接受的载体成分时，消除了可还原糖与下列通式（I）所表示的化合物或其盐之间的接触。
• NOVEL CRYSTALS OF SUBSTITUTED PHENYLALKANOIC ACID AND METHOD OF PRODUCING THE SAME
  申请人：ARIMOTO Yuichi

  公开号：US20090312386A1

  公开（公告）日：2009-12-17

  [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. [Means] Crystals of any compound among 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, and methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate, and methods of producing the same are provided.

  【目的】本发明提供使用3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸、甲基3-[4-(茚-2-氧基)-3-(1-甲基-1H-吲唑-5-基)-5-硝基苯基]丙酸酯或甲基3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸酯作为药物时，提供更优选的方面或改进的方法。 【手段】本发明提供3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸、甲基3-[4-(茚-2-氧基)-3-(1-甲基-1H-吲唑-5-基)-5-硝基苯基]丙酸酯和甲基3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸酯中的任何化合物的晶体以及其制备方法。
• NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID ESTER AND PROCESS FOR PRODUCING THE SAME
  申请人：SHODA Motoshi

  公开号：US20100234440A1

  公开（公告）日：2010-09-16

  [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. [Means] Crystals of any compound among 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, and methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate, and methods of producing the same are provided.

  【对象】在使用3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸、甲基3-[4-(茚-2-氧基)-3-(1-甲基-1H-吲唑-5-基)-5-硝基苯基]丙酸酯或甲基3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸酯作为药物时，提供了更可取的方面或改进的方法。 【方法】提供了3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸、甲基3-[4-(茚-2-氧基)-3-(1-甲基-1H-吲唑-5-基)-5-硝基苯基]丙酸酯和甲基3-[3-氨基-4-(茚-2-氧基)-5-(1-甲基-1H-吲唑-5-基)苯基]丙酸酯中的任何化合物的晶体以及其制备方法。